Latest news with #PetVivo
Miami Herald
01-08-2025
- Business
- Miami Herald
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team
Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team NEW YORK CITY, NEW YORK / ACCESS Newswire / August 1, 2025 / New to The Street, the nation's leading financial media platform, proudly announces the broadcast of Show #682, airing this evening at 9:30 PM PST on Bloomberg Television as sponsored programming. This episode showcases transformative companies driving innovation across artificial intelligence, veterinary health, blockchain, healthcare SaaS, and pharmaceutical sectors. Featured Interviews on Episode #682 Include: - DataVault Holdings Inc. (NASDAQ:DVLT)CEO Nathaniel Bradley highlights the company's enterprise expansion, announcing the debut of AI agents powered by IBM This breakthrough enables corporate clients to securely monetize data using compliant, intelligent automation. DataVault AI's growing partnerships with IBM and other tech leaders demonstrate its position at the forefront of AI + Web3 convergence-empowering businesses to unlock value from untapped data assets. - PetVivo Holdings Inc. (NASDAQ:PETV)PetVivo continues its rapid commercial rollout of SPRYNG with OsteoCushion Technology, now adopted by over 1,200 veterinary clinics across the United States. The company is also making strategic inroads into the equine space through its new partnership with Commonwealth Thoroughbreds-aimed at advancing equine joint wellness and performance across top-tier racing circuits. This milestone reflects PetVivo's growing leadership in the $3B+ animal therapeutics market, with SPRYNG providing a drug-free, minimally invasive solution to joint pain in companion and performance animals. - Health In TechHealth In Tech presents its disruptive approach to benefits administration via an end-to-end SaaS platform designed for brokers, employers, and TPAs. The solution's intuitive interface and real-time quoting tools deliver speed, efficiency, and scalability for today's healthcare benefits landscape. - FLOKILeaders from FLOKI discuss their growing DeFi ecosystem and global presence, with recent expansions into financial education tools, community governance, and real-world payment infrastructure. - NRx Pharmaceuticals (NASDAQ:NRXP)CEO Dr. Jonathan Javitt offers an update on the company's late-stage pharmaceutical developments for bipolar depression, PTSD, and other CNS disorders, while continuing to advance FDA engagement for its proprietary pipeline. National TV Commercial Support: High-frequency national commercials and campaigns are airing in conjunction with the show for: NRx PharmaceuticalsArriveAISustainable Green Team (SGTM)MUSQ - The Music ETF Campaigns are focused on national television and the #1 NYC DMA, targeting high-investor-density zones and financial news audiences. Cross-Platform Distribution & Outdoor Exposure: All interviews are distributed via New to The Street's YouTube channel (3.1M+ subscribers) and promoted across LinkedIn, Twitter/X, Instagram, and Facebook. Clients also receive billboard exposure across Times Square, Wall Street, and NYC Financial District bus shelters, with additional reach through syndicated earned media on ABC, NBC, and CBS local affiliates. July Performance: A Record Month for Client Renewals July saw 9 clients signing new or renewed media agreements across broadcast, digital, and outdoor campaigns - driven by demand for New to The Street's unmatched national visibility and investor engagement platform. These results position the network as the leading multi-channel awareness engine for small- to mid-cap growth companies. About New to The Street:New to The Street is a premier television business brand broadcasting sponsored programming on Fox Business and Bloomberg Television. With a loyal YouTube following of over 3.1 million subscribers, iconic outdoor billboard access, and strong earned media distribution, New to The Street delivers a 360-degree media solution for public and private companies seeking scale, credibility, and conversion. Media Contact:Monica BrennanMonica@ SOURCE: New to The Street
Business Upturn
30-07-2025
- Business
- Business Upturn
PetVivo Holdings Inc. to Trade on OTCQX Best Market
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively 'PetVivo' or the 'Company'), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, such as Spryng® with OsteoCushion® Technology and PrecisePRP®, today announced that the Company has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market. PetVivo Holdings Inc. begins trading today on OTCQX under the symbol 'PETV.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on . The OTCQX Market is designed for established, investor-focused U.S. and international companies. The OTCQX Market has 625 securities as of today, while the broader OTC Markets Group includes approximately 12,000 securities. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. PetVivo's signature product, SPRYNG with OsteoCushion Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis. PetVivo's other innovative product, PrecisePRP, is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter. 'Qualifying to trade on the OTCQX Best Market is a significant milestone for our Company,' said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. 'This upgrade reflects our continued commitment to transparency, strong corporate governance, and delivering long-term value to our shareholders. Trading on OTCQX will enhance our visibility within the investment community and provide greater liquidity and accessibility for investors as we continue to execute on our strategic growth initiatives.' For more information about PetVivo Holdings, Inc. please contact [email protected] or visit , and . About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for equine and companion animals. The Company's strategy is to leverage human therapies for the treatment of equine and companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. CONTACT: John Lai, CEO PetVivo Holdings, Inc. Email: [email protected] (952) 405-6216
Yahoo
26-06-2025
- Business
- Yahoo
PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET
MINNEAPOLIS, MN, US, June 26, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Monday, June 30, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal fourth quarter and year ended March 31, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. Date: Monday, June 30, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time) Toll-free dial-in number: +1 253 205 0468 Conference ID: 83424004566 Passcode: 352845 Webcast (live and replay): click here A replay of the webcast will be available through the same link following the conference call. The conference call webcast replay will also be available via a link in the Investors section of the company's website at About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. CONTACT: John Lai, CEO PetVivo Holdings, Inc. Email: info1@ (952) 405-6216 Forward-Looking Statements: The foregoing material may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
09-06-2025
- Business
- Miami Herald
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation's leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand's flagship long-form format. Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street's position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale. Watch the full specials here: IMG Academy: PetVivo: Acurx Pharmaceuticals: Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers. Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement. For media, sponsorship, or booking inquiries, contact:Monica BrennanMonica@ About New to The Street:New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen. SOURCE: New To The Street
Associated Press
09-06-2025
- Business
- Associated Press
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation's leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand's flagship long-form format. Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street's position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale. Watch the full specials here: 'These are not typical interviews-they're broadcast-quality mini-documentaries that resonate across investor and consumer audiences alike,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'We're combining Wall Street-level insight with storytelling that connects emotionally and visually. Companies are seeing it translate directly into visibility and traction.' Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers. Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement. 'The data is crystal clear-audiences are spending more time with high-quality, long-form content,' added Caruso. 'This format allows companies to fully control their narrative, showcase innovation, and build trust-all while generating viewership numbers that rival traditional media.' For media, sponsorship, or booking inquiries, contact: Monica Brennan [email protected] About New to The Street: New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen. SOURCE: New To The Street press release
